Research programme: kinase-directed anti-HIV agents - GPC Biotech/Galapagos
Latest Information Update: 22 Jan 2007
At a glance
- Originator Galapagos NV; GPC Biotech AG
- Class
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
- 02 Mar 2005 Axxima Pharmaceuticals has been acquired and merged into GPC Biotech AG
- 22 Jul 2002 Preclinical trials in HIV infections treatment in Germany (unspecified route)